Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis

Chest

Volumn 148, Issue 1, 2015, Pages 196-201

  Lederer, David J ^a   Bradford, Williamson Z ^b   Fagan, Elizabeth A ^b   Glaspole, Ian ^c   Glassberg, Marilyn K ^d   Glasscock, Kenneth F ^b   Kardatzke, David ^b   King, Talmadge E ^e   Lancaster, Lisa H ^f   Nathan, Steven D ^g   Pereira, Carlos A ^h   Sahn, Steven A ⁱ   Swigris, Jeffrey J ^j   Noble, Paul W ^k  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b InterMune Inc   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g INOVA FAIRFAX HOSPITAL   (United States)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j DEPARTMENT OF MEDICINE   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; CLINICAL EVALUATION; DATA ANALYSIS; DRUG EFFICACY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT DURATION; ADULT; AGED; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84937574973     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2817     Document Type: Article

References (24)

1. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044-1048.
2. Rose DM, Montgomery AB. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013;187(11):1269.
3. Bradford WZ, Cohen AH, Leff JA. Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187(11):1269-1270.
4. King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189(7):825-831.
5. O'Connell OJ, Egan JJ. The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;189(7):765-767.
6. Lederer DJ. Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward. Eur Respir J. 2013;42(6):1446-1448.
7. Koczulla AR. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014;371(8):781.
8. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382-1389.
9. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538-542.
10. Flaherty KR, Mumford JA, Murray S, et al . Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-548.
11. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639-644.
12. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest. 2005;127(1):171-177.
13. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):830-836.
14. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-466.
15. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67(5):407-411.
16. Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax. 2013;68(4):309-310.
17. King TE Jr, Bradford WZ, Castro-Bernardini S, et al ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
18. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials . Control Clin Trials. 1999;20(5):408-422.
19. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18(11):1341-1354.
20. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769.
21. Taniguchi H, Ebina M, Kondoh Y, et al Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35(4):821-829.
22. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087.
23. Richeldi L, du Bois RM, Raghu G, et al INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
24. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G; Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093-2101.